Gossamer Bio Stock Price, News & Analysis

Gossamer Bio (NASDAQ: GOSS) reported third-quarter 2025 results and a program update on November 5, 2025. Key corporate facts: cash, cash equivalents and marketable securities of $180.2 million as of September 30, 2025, with management saying this provides runway into 2027. The Phase 3 PROSERA study completed enrollment at 390 PAH patients and topline results are expected in February 2026. The first site was activated for the registrational Phase 3 SERANATA study in PH‑ILD (~480 patients randomized across two doses and placebo). Q3 2025 revenue from Chiesi was $13.3M; net loss was $48.2M (Q3 2024: $30.8M).

Gossamer Bio (NASDAQ:GOSS) has entered into an option agreement to acquire Respira Therapeutics, a Samsara BioCapital portfolio company. The deal centers around RT234, a first-in-class inhaled vardenafil powder being developed as an as-needed (PRN) treatment for pulmonary hypertension (PH).

As part of the agreement, Gossamer will issue 2.5 million shares upfront and an additional 1.5 million shares upon exercising the acquisition option. The deal includes success-based milestone payments and royalties on potential RT234 sales. During the two-year option period, Gossamer will fund CMC development activities for RT234.

Gossamer Bio (NASDAQ:GOSS) has entered into an option agreement to acquire Respira Therapeutics and its lead candidate RT234, an inhaled, on-demand vardenafil treatment for pulmonary hypertension. The deal structure involves no upfront cash, with Gossamer issuing 2.5 million shares (1% of outstanding shares) at signing and 1.5 million additional shares upon option exercise.

RT234 is designed to provide rapid symptom relief for PAH and PH-ILD patients, addressing an unmet need where no on-demand treatments currently exist. The drug has shown promising results in two Phase 2 studies, demonstrating improvements in hemodynamics and functional measures. The company plans to pursue a 505(b)(2) regulatory pathway in the US, with potential clinical trials starting no earlier than 2027.

Gossamer Bio (NASDAQ:GOSS) has announced five scientific presentations featuring seralutinib at the upcoming European Respiratory Society (ERS) Congress 2025 in Amsterdam. The presentations include one oral and four poster sessions highlighting seralutinib's potential in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The presentations will showcase various aspects of seralutinib's therapeutic potential, including its effects on fibrotic pathways, vascular inflammation reduction, anti-fibrotic effects in patient-derived models, impact on pulmonary artery vessel volume, and its role in decreasing endotrophin production. The drug is being jointly developed by Gossamer Bio and the Chiesi Group under a global collaboration agreement.

Gossamer Bio (Nasdaq: GOSS), a late-stage clinical biopharmaceutical company, announced the approval of inducement grants to two non-executive employees. The grants consist of non-qualified stock options to purchase up to 87,500 shares of common stock under the company's 2023 Inducement Plan.

The options have an exercise price of $2.94 per share, matching GOSS's closing price on September 5th, 2025. The options feature a ten-year term with a four-year vesting schedule: 25% vesting after one year, followed by monthly installments over 36 months, contingent on continued employment.

Gossamer Bio (NASDAQ:GOSS), a late-stage clinical biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2025. The company, which focuses on developing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present at the Cantor Global Healthcare Conference (September 3rd), Wells Fargo Healthcare Conference (September 4th), and H.C. Wainwright Global Healthcare Conference (September 9th).

The presentations include fireside chats and one-on-one meetings with investors, with events taking place in New York and Boston.

Gossamer Bio (Nasdaq: GOSS), a late-stage clinical biopharmaceutical company, announced the approval of inducement grants to three non-executive employees. The Compensation Committee approved non-qualified stock options to purchase up to 168,750 shares of common stock under the company's 2023 Inducement Plan.

The options have an exercise price of $2.16 per share, matching Gossamer's closing price on August 5th, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.

Gossamer Bio (NASDAQ: GOSS) reported Q2 2025 financial results and provided updates on its lead drug candidate seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for PAH treatment, with topline results expected in February 2026. The study's primary endpoint is change in six-minute walk distance at week 24.

Financial highlights include $212.9 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for PH-ILD in Q4 2025, targeting approximately 480 patients.

Gossamer Bio (GOSS) has completed enrollment for its Phase 3 PROSERA study evaluating seralutinib for pulmonary arterial hypertension (PAH) treatment. The study, conducted in collaboration with Chiesi Group, enrolled 390 patients and expects to announce topline results in February 2026. The double-blind, placebo-controlled trial evaluates seralutinib against placebo, with patients receiving treatment for up to 48 weeks. The primary endpoint measures change in six-minute walk distance at week 24. The enrolled patient population shows promising baseline characteristics, with 74% being Functional Class III patients and a mean 6MWD of 374 meters. The study leverages enrichment criteria including REVEAL Lite 2 Risk Score to identify patients more likely to demonstrate significant benefits.